UNIVERSITY OF LEEDS

This is a repository copy of *Irritable bowel syndrome*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/166983/>

Version: Accepted Version

Article:

Ford, AC orcid.org/0000-0001-6371-4359, Sperber, AD, Corsetti, M et al. (1 more author) (2020) Irritable bowel syndrome. *The Lancet*. ISSN 0140-6736

[https://doi.org/10.1016/S0140-6736\(20\)31548-8](https://doi.org/10.1016/S0140-6736(20)31548-8)

© 2020 Elsevier Ltd. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Accepted 3rd July 2020

Title: Irritable Bowel Syndrome.

Short running head: Irritable Bowel Syndrome.

Authors: Professor Alexander C. Ford MD^{1,2}, Professor Ami D. Sperber MD.³, Maura Corsetti PhD^{4,5}, Professor Michael Camilleri MD⁶.

¹Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.

²Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.

³Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

⁴NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, UK.

⁵University of Nottingham and Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK.

⁶Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic, Rochester, MN, USA.

Abbreviations:	5-HT	5-hydroxytryptamine
	CBT	cognitive behavioural therapy
	CI	confidence interval
	CRC	colorectal cancer
	cGMP	Cyclic GMP
	EMA	European Medicines Agency
	FDA	Food and Drug Administration

26	FODMAPs	fermentable oligo-, di-, and mono-saccharides and
27		polyols
28	IBD	inflammatory bowel disease
29	IBS	irritable bowel syndrome
30	IBS-C	irritable bowel syndrome with constipation
31	IBS-D	irritable bowel syndrome with diarrhoea
32	IBS-M	irritable bowel syndrome with mixed stool pattern
33	IBS-U	irritable bowel syndrome unclassified
34	MC	microscopic colitis
35	OR	odds ratio
36	PI-IBS	post-infection IBS
37	RCT	randomised controlled trial
38	RR	relative risk
39	SeHCAT	23-seleno-25-homotaurocholic acid
40	SSRI	selective serotonin reuptake inhibitor
41	SIBO	small intestinal bacterial overgrowth
42	TCA	tricyclic antidepressant

43

44 **Correspondence:** Professor Alexander C. Ford
45 Leeds Gastroenterology Institute
46 Room 125
47 4th Floor
48 Bexley Wing
49 St. James's University Hospital
50 Beckett Street

51 Leeds
52 United Kingdom
53 LS9 7TF
54 Email: alexf12399@yahoo.com
55 Telephone: +441132684963

56

57 **Keywords:** IBS, epidemiology, diagnosis, pathophysiology, drug therapy,
58 psychological therapy

59

60 **Word count:** 5102

61

ABSTRACT

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder whose symptoms include abdominal pain associated with a change in stool form or frequency. The condition affects between 5% and 10% of otherwise healthy individuals in the community at any one point in time and, in most people, runs a relapsing and remitting course. The best described risk factor is acute enteric infection, but IBS is also more common in people with psychological co-morbidity, and in young adult females. The pathophysiology of IBS remains incompletely understood, but it is well established that there is disordered communication between the gut and the brain, leading to motility disturbances, visceral hypersensitivity, and altered central nervous system processing. Other less reproducible mechanisms may include genetic associations, alterations in gastrointestinal microbiota, and disturbances in mucosal and immune function. In most people the diagnosis can be made based on the clinical history, with limited, judicious, use of investigations, unless alarm symptoms such as weight loss or rectal bleeding are present, or there is a family history of inflammatory bowel disease or coeliac disease. Once the diagnosis is made, an empathetic approach is key, and can improve quality of life and symptoms, and reduce health care expenditure. The mainstays of treatment include patient education about the condition, dietary changes, soluble fibre, and antispasmodic drugs. Other treatments tend to be reserved for those with more severe symptoms; these include central neuromodulators, intestinal secretagogues, drugs acting on 5-hydroxytryptamine or opioid receptors, or minimally absorbed antibiotics (all of which are selected according to predominant bowel habit), and psychological therapies. The increased understanding of the pathophysiology of IBS in the last 10 years has led to a healthy pipeline of novel drugs in development.

INTRODUCTION

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that has a substantial impact on quality of life and social functioning.^{1,2} The pathophysiology of IBS is only partially understood.³ It affects between 5% and 10% of the general population,⁴ and is characterised by recurrent abdominal pain in association with abnormal stool form or frequency.⁵ Treatment aims to improve both abdominal pain and bowel habit, but often is targeted towards the most troublesome symptom. First-line therapies include dietary changes, soluble fibre, and antispasmodic drugs; in patients with more severe symptoms, treatments include central neuromodulators, including low-dose tricyclic antidepressants (TCAs), intestinal secretagogues, drugs acting on opioid or 5-hydroxytryptamine (5-HT) receptors, antibiotics, and psychological therapies.⁶ The annual direct and indirect costs related to IBS are estimated to be up to €8 billion in Europe,⁷ ¥123 billion in China,⁸ and in excess of \$10 billion in the USA.⁹

SEARCH STRATEGY AND SELECTION CRITERIA

We searched the medical literature using MEDLINE, EMBASE, EMBASE Classic, and the Cochrane central register of controlled trials during the last 10 years with the terms “irritable bowel syndrome”, “epidemiology”, “prevalence”, “incidence”, “aetiology”, “pathophysiology”, “diagnosis”, “investigation”, “management”, “therapy”, and “treatment” in order to identify pertinent articles. In addition, we searched clinicaltrials.gov for unpublished trials. We included only publications in English, and selected those articles whose findings were, in our view, of the greatest importance, favouring randomised controlled trials, meta-analyses, and network meta-analyses.

EPIDEMIOLOGY

The most recent symptom-based diagnostic criteria for IBS, the Rome IV criteria, were developed by consensus among experts in functional gastrointestinal disorders. The criteria consist of abdominal pain associated with an alteration in either stool form or frequency, occurring for at least 6 months.⁵ Patients are subgrouped according to predominant stool pattern, using the Bristol stool form scale:¹⁰ IBS with diarrhoea (IBS-D), IBS with constipation (IBS-C), IBS with mixed stool pattern (IBS-M), and IBS unclassified (IBS-U) (Table 1). Methodological limitations make it difficult to obtain reliable estimates of prevalence,¹¹ particularly because, in the absence of universally accepted biomarkers of disease, the diagnosis relies on self-reported symptom clusters. However, as organic gastrointestinal disease in the community is relatively rare, and a diagnosis of IBS is made based on the presence of typical symptoms, population-based epidemiological studies provide a close approximation of true prevalence, which is between 5% and 10% in most geographical regions (Figure 1).⁴

Various iterations of these symptom-based diagnostic criteria have resulted in differences in reported prevalence, but disease impact is substantial even in people felt to have IBS, but not meeting such criteria.¹² In addition, both symptom interpretation and reporting are influenced by cultural factors, and can vary among ethnic groups.¹¹ Prior to publication of the Rome IV criteria in 2016,⁵ two systematic reviews examining global prevalence of IBS were conducted.^{4,13} The first reported a pooled prevalence of 11.2% (95% confidence interval (CI) 9.8% to 12.8%),¹³ ranging from 1.1% in Iran, using the Rome III criteria, to 45% in Pakistan using Rome II. The second review reported a global prevalence of 8.8% (95% CI 8.7% to 8.9%).⁴ Prevalence varied widely, from 1.1% in France using the Rome II criteria, and Iran using Rome III, to 35.5% in Mexico using Rome II.¹⁴ Thus,

despite commonly accepted prevalence ranges, variation in estimates between studies is large, partly due to methodological heterogeneity.

Findings from a Rome Foundation 33-nation cross-sectional survey, examining worldwide prevalence and burden of functional gastrointestinal disorders in over 73,000 individuals in 26 countries, were published in 2020.¹⁵ Using Rome IV criteria, prevalence rates ranged between 2% and 6%, with a pooled prevalence of 4.1%. In countries where both Rome III and IV criteria were applied, pooled prevalence fell from 10.1% with Rome III to 3.8% for Rome IV. However, there remains a dearth of prevalence data from Africa, Eastern Europe, and the Middle East.

RISK FACTORS

In two systematic reviews, rates of IBS were significantly higher in females^{4,13} and, when 14 studies were pooled, prevalence was lower in those aged ≥ 50 (odds ratio (OR) 0.75; 95% CI 0.62 to 0.92) compared with those aged < 50 years.¹³ There are no reliable data on IBS and socio-economic status. IBS is more common in patients with functional somatic syndromes, such as fibromyalgia and chronic fatigue.¹⁶ Many other psychosocial, biological, and environmental factors are associated with IBS, and may influence symptom severity (Figure 2). However, it is unclear if these are genuine risk factors; most studies are cross-sectional, and lack the temporal element needed to determine cause and effect.

Perhaps the best-recognised risk factor for IBS, observed in approximately 10% of patients,¹⁷ is prior acute enteric infection. This is termed post-infection IBS (PI-IBS), and can occur after bacterial, viral, or protozoal infection.¹⁸ In one retrospective cohort study, even non-specific gastrointestinal infections, which comprised the vast majority of cases, were associated with an equally high risk of PI-IBS to culture-confirmed bacterial or viral infections.¹⁹ A meta-analysis of 45 observational studies reported a four-fold increase in

odds of developing IBS in exposed individuals 12 months post-infection (OR 4.2; 95% CI 3.1 to 5.7).¹⁸ Risk factors for development of PI-IBS included female sex, antibiotic exposure, psychological distress preceding the illness, and severity of infection.¹⁸ Prognosis may be better than in those with a non-infectious cause although, in one longitudinal follow-up study, 15% of those with PI-IBS remained symptomatic 8 years later.²⁰

PATHOPHYSIOLOGY

The biopsychosocial model to explain symptoms of abdominal pain and disordered bowel habit in IBS conceptualised a genetic predisposition, where adverse events in early life, psychological factors, or gastrointestinal infections then trigger alterations in the enteric nervous system, which controls gastrointestinal motor, sensory, mucosal barrier, and secretory responses (Figure 3).²¹

“Traditional” Mechanisms: The Brain-gut Axis, Stress, Visceral Hypersensitivity, and Altered Motility

In addition to the psychological component of IBS,²² gut-brain communication is bidirectional. Prospective longitudinal studies demonstrate that a subset of patients experience gastrointestinal symptoms first,^{23,24} and psychological distress later. Gastrointestinal infection and psychological disorders appear to be distinct risk factors, contributing additively to the development of both PI-IBS and the extra-intestinal symptoms frequently linked to IBS, such as chronic fatigue.¹⁹

Altered visceral sensation in IBS is characterised by central abnormalities in sensory, emotional arousal, and prefrontal cortical regions of the brain. Alterations in the descending pathways modulating sensation, and peripheral mechanisms are also involved in the pathogenesis of visceral pain.²⁵ On average, about 60% of patients exhibit increased

sensitivity of the gut to different physiological stimuli.^{26,27} Disordered motility in IBS is manifested by abnormal colonic myoelectric activity,²⁸ repetitive contractions of the small intestine and colon, associated with abdominal pain, and alterations in gastrointestinal or colonic transit.^{29,30} Accumulation of different mechanisms (psychological, sensory, and motor) increases both gastrointestinal and non-gastrointestinal symptom severity, as well as impairments in quality of life.^{31,32}

The Gut Microenvironment

As many IBS patients report that their symptoms are associated with eating, or eliminating, certain foods,³³ it has been assumed that diet and, more recently, gastrointestinal microbiota are involved in pathophysiology.

Dietary FODMAPs and Disaccharide Maldigestion

Fermentable oligo-, di-, and mono-saccharides and polyols (FODMAPs) are present in high levels in some fruits, artificial sweeteners, legumes, and green vegetables, and are poorly absorbed in all individuals. They have fermentative and osmotic effects, which may contribute to symptoms in some patients.³⁴ Although randomised controlled trials (RCTs) have confirmed that dietary modification can affect IBS symptoms, so far, they have not confirmed symptom generation by a specific food. Patients with IBS exhibit comparable increases in small intestinal water content and colonic volume to FODMAPs to those seen in healthy individuals, but symptomatic responses are greater in IBS, supporting the role of visceral hypersensitivity.³⁵ Dietary disaccharide maldigestion may induce symptoms secondary to osmotic diarrhoea and gas production following fermentation of unabsorbed sugars,^{36,37} due to disaccharidase deficiency, classically lactase or, as more recently

demonstrated in 4% of patients with IBS,^{38,39} sucrase-isomaltase, which digests sucrose and starch.

The Microbiome

Although some studies demonstrate that patients with IBS have a different gastrointestinal microbiome, compared with healthy controls,^{40,41} the role of the microbiota is still questioned, particularly because what constitutes a “healthy” microbiome remains unclear. A systematic review demonstrated few consistent findings in IBS (possibly because age, sex, race, diet, and antibiotic intake were not controlled for in included studies), and certainly no microbiome signature differentiating IBS subgroups.⁴² Antibiotics change the intestinal microbiome, and have been associated with development of IBS.⁴³ Small intestinal bacterial overgrowth (SIBO), has also been implicated,⁴⁴ but its role is controversial due, in large part, to limitations of available diagnostic tests, such as glucose and lactulose breath tests⁴⁵ and culture of jejunal aspirates.⁴⁶

Bile Acids

Up to 25% of patients who meet criteria for IBS-D have idiopathic bile acid diarrhoea, demonstrated by abnormal retention following 23-seleno-25-homotaurocholic acid (SeHCAT) scanning,⁴⁷ or total 48-hour faecal bile acid levels.⁴⁸ The latter correlated with stool number and form, and colonic transit, in one case series of patients.⁴⁹ Excess faecal bile acids in IBS-D appeared to be associated with dysbiosis, specifically a Clostridia-rich microbiota, in a case-control study.⁵⁰

Barrier Function and Immune Activation

Acute gastrointestinal infections induce changes in intestinal permeability and the microbiome.⁵¹ This may promote activation of immune cells, including T-lymphocytes and mast cells, in the gastrointestinal epithelium,⁵² leading to cytokine release, which can modify neural control of gastrointestinal motor, sensory, and secretory functions. Pathophysiological alterations can last for years. For example, in PI-IBS neuronal signalling remained sensitised 2 years after the infection.⁵³ Other investigators have reported increased gastrointestinal permeability and elevated immune cell counts, even in patients with IBS without an infective aetiology.^{54,55}

Genetics

Although research into the genetics of IBS lags behind other conditions, like inflammatory bowel disease (IBD), genome-wide association studies have provided associations with variants on chromosome 9 (9q31.2 locus) that are linked to the functions of diverse ion channels and autonomic dysfunction,⁵⁶ and mutations in the sucrase-isomaltase gene,^{38,39} as previously discussed. In addition, approximately 2% of IBS patients carry missense mutations in *SCN5A*,⁵⁷ which alters the function of the voltage-gated mechanosensitive Na⁺ channel Nav1.5, and affects smooth muscle function and mechanical sensitivity. In twin studies, concordance of a diagnosis of IBS is commoner in monozygotic, compared with dizygotic twins; however, having a parent with IBS is a stronger predictor, suggesting that environmental factors such as learned illness behaviour are more important.⁵⁸

CLINICAL PRESENTATION AND DIFFERENTIAL DIAGNOSIS

Although IBS is a multifactorial and heterogeneous disorder, there are some typical features. The condition is most common among females aged 20 to 40 years,^{4,13} although in

some countries appears more prevalent in males.⁵⁹ It can occur at any age;¹⁵ the average age of participants in clinical trials of novel drugs in IBS is around 45 years, illustrating the broad age range of patients. Coexistent mood problems and extra-intestinal symptoms, including back pain, gynaecological and bladder symptoms, headache, and fatigue are common,^{60,61} as is overlap with other functional gastrointestinal disorders.⁶² The presence of abdominal pain is essential to the definition of IBS. Accordingly, the differential diagnosis is broad, but other features help narrow this down. Firstly, as IBS is a chronic disorder, causes of acute abdominal pain are ruled out. Secondly, the pain is recurrent, but it is intermittent rather than continuous. Thirdly, pain is usually in the lower abdomen, although Asian patients may report upper abdominal pain.⁶³ Finally, and most critically, pain in IBS is associated with defaecation, and occurs at the time when the patient experiences alterations in stool frequency or consistency.⁵ Although IBS is subgrouped according to predominant stool pattern,⁵ this fluctuates in many patients.⁶⁴ Abdominal bloating is not a cardinal symptom but is very common, and supports the diagnosis, particularly if it is diurnal. It is often accompanied by visible abdominal distension.⁶⁵

In order to understand the precise meaning of terms such as diarrhoea or constipation, as well as the impact of the disorder on social functioning and wellbeing, a thorough history is essential. The Bristol stool form scale is a useful tool to assess stool consistency in the clinic, and can be used to direct treatment, which is discussed later. A detailed history helps differentiate between IBS and other disorders characterised by abdominal pain in association with altered bowel habit, including coeliac disease, IBD, colorectal cancer (CRC), and microscopic colitis (MC). These are considered below.

INVESTIGATIONS

Although there is no universally accepted biomarker for IBS, exhaustive investigation to exclude an organic cause for the symptoms is discouraged, as this is expensive, and many patients are not reassured by such an approach.⁶⁶ Once a clinical diagnosis of IBS is made, it is unlikely to be revised, even during extended follow-up.⁶⁷ Guidelines recommend a “positive” diagnosis using symptom-based diagnostic criteria, such as the Rome criteria, and minimising investigations (Figure 4).⁶ Although the Rome IV criteria have yet to be validated independently, in secondary care sensitivity of the Rome III criteria was 68.8%, specificity 79.5%, and positive and negative likelihood ratios 3.35 and 0.39, respectively.⁶⁸ The addition of other features from the clinical history, including absence of nocturnal stools, presence of anxiety, depression, or extra-intestinal symptoms, and a normal full blood count and C-reactive protein enhances the diagnostic performance of the Rome III criteria.⁶⁹

There is little evidence to support a routine panel of blood tests, other than full blood count, C-reactive protein, and serological screening for coeliac disease, which has a prevalence of 1% in most Western countries, and is an important differential diagnosis. A meta-analysis demonstrated an almost three-fold higher odds of positive coeliac serology in patients with symptoms suggestive of IBS (OR 2.75; 95% CI 1.35 to 5.61), compared with healthy controls, irrespective of predominant stool pattern.⁷⁰

Whether any further investigations are required in a patient with new onset symptoms depends, to some extent, on bowel habit, unless alarm symptoms or signs (Table 2) are present.⁷¹ The latter are an indication for urgent colonoscopy. Colonoscopy should also be performed if the patient is aged ≥ 50 years and has not already had age-related CRC screening. In addition, unexplained rectal bleeding or iron-deficiency anaemia needs investigation, regardless of age. A family history of coeliac disease, IBD, or CRC is also relevant. In a patient with IBS-C, the diagnosis is secure, unless there are obstructive

symptoms (excessive straining, sense of incomplete rectal evacuation, or digitation of the anus to facilitate defaecation) or digital rectal examination suggests a defaecatory disorder,⁷² which is the result of incoordination of the normal functions required for rectal evacuation. If present, anorectal manometry with balloon expulsion testing may be helpful, as the treatment of choice for these conditions is biofeedback,⁷³ rather than dietary or drug therapy.

In a patient with diarrhoea, there may be greater concern for a missed organic diagnosis. Faecal calprotectin, which is a cytosol protein released by neutrophils, can differentiate between IBS and IBD,^{74,75} avoiding the need for colonoscopy, for which the yield is low. In a cross-sectional survey of almost 500 patients with IBS, only 0.4% of patients were found to have IBD at colonoscopy, 1.5% MC, and there were no cases of CRC.⁷⁶ MC is more common in females over the age of 45 years. There are other clues to MC as a cause of symptoms, rather than IBS, which should lead to consideration of colonoscopy to obtain colonic biopsies. These include the fact that the presence of abdominal pain is variable, duration of symptoms tends to be shorter, and patients often have coexistent autoimmune disease, report nocturnal diarrhoea and weight loss, or are taking drugs, such as a non-steroidal anti-inflammatory drug or a proton pump inhibitor.^{77,78}

Bile acid diarrhoea is another important differential in patients presenting with IBS-D, as its estimated population prevalence is 1%. It can be diagnosed using SeHCAT scanning, a fasting serum 7 α -hydroxy-4-cholesten-3-one, fibroblast growth factor-19, or 48-hour faecal bile acid excretion,⁷⁹ but these are not universally available. A therapeutic trial of a bile acid sequestrant as a surrogate diagnostic test is an alternative, although it is unclear what dose should be used, and problems with medication compliance may compromise its utility.⁸⁰

The reported association between SIBO and IBS is contentious.⁴⁴ Investigations to exclude SIBO should only be considered in patients with clear risk factors, such as previous gastric or intestinal surgery, or known structural abnormalities, including jejunal

diverticulosis. Hydrogen breath tests may be falsely positive, as they are a marker for rapid transit.⁴⁵ Instead, culture of jejunal aspirates should be considered if SIBO is suspected.⁸¹

NATURAL HISTORY AND IMPACT

The typical course in IBS consists of fluctuating symptoms, in terms of bowel habit.⁶⁴ Incidence of new-onset IBS was approximately 1.5% to 2.5% per year, over 10 to 12 years, in three longitudinal studies.⁸²⁻⁸⁴ However, prevalence remains stable, because the number of people developing new symptoms is matched by the number whose symptoms disappear or fluctuate to another functional gastrointestinal disorder.^{83,84} IBS causes morbidity, but not mortality,⁸⁵ and affects quality of life¹ to the same degree as organic gastrointestinal disorders such as Crohn's disease.⁸⁶

It also impacts work productivity,^{1,2} social integration, and psychosocial factors, such as general and gut-related anxiety, depression, and somatisation.^{60,87} Some of these associations are bidirectional,^{23,24} so that psychosocial factors can exacerbate IBS symptoms, and the illness experience, and vice versa. One cross-sectional survey showed the impact on daily activity differs according to stool pattern; those with IBS-D avoided travel or leaving the house, due to concerns about toilet access, and those with IBS-C avoided sexual intercourse and reported difficulty concentrating.⁸⁸ Associations with severity include overlap with other functional gastrointestinal disorders,⁶² and consulter status.⁸⁹ However, those who consult with symptoms also have poorer quality of life, increased rates of psychological symptoms, and reduced coping.⁸⁹ There is a direct correlation between number of overlapping functional gastrointestinal disorders, reduced quality of life, and increased health care utilisation and gastrointestinal surgery.⁶² Patients are willing to accept a 1% median risk of sudden death in return for a 99% chance of cure of their symptoms with a hypothetical medication.⁹⁰

MANAGEMENT

As no medical therapy is proven to alter the natural history of IBS, and the majority of RCTs are only conducted over a 12-week period meaning that their long-term efficacy is unknown, an empathetic approach is key. This can improve quality of life and symptoms,⁹¹ reduce health care visits, and enhance adherence to treatment.^{92,93} Management should commence with explanation of the disorder, its pathophysiology, and natural history. In fact, structured patient education about the condition led to a significantly greater improvement in symptoms, compared with written information, in one RCT.⁹⁴ Treatment is directed towards the predominant symptom, with a realistic discussion of the limitations of available therapies, in order to manage expectations, as most improve symptoms in only 25% to 30% of patients (Table 3), and have only been tested in referral populations. The final decision as to the choice of treatment should be the patient's, after they receive full information on available options in a dialogue with the doctor.

Lifestyle, Diet, and Probiotics

The effect of lifestyle changes in IBS has not been well studied; in a small RCT of physiotherapist-administered exercise, symptoms improved significantly, compared with a control arm with no changes to physical activity.⁹⁵ Traditionally, patients with IBS were told to increase dietary fibre intake. However, bran may exacerbate symptoms,⁹⁶ although ispaghula husk was more efficacious than placebo in a meta-analysis of seven RCTs (relative risk (RR) of remaining symptomatic 0.83; 95% CI 0.73 to 0.94).⁹⁷ Several RCTs demonstrate that FODMAP restriction leads to an improvement in IBS symptoms, compared with habitual diet.^{98,99} However, other RCTs suggest that "traditional" dietary advice to eat small regular meals, avoid known trigger foods, and reduce alcohol and caffeine, is as effective as a low FODMAP diet.^{100,101} Long-term FODMAP restriction may lead to

deleterious alterations in the microbiome.¹⁰² FODMAPs should, therefore, be reintroduced to tolerance after a limited period of restriction, but RCTs conducted to date only examine the effect on symptoms during FODMAP elimination. There is little evidence to support benefit of a gluten-free diet in IBS.¹⁰³ However, as wheat contains fructans, which is a FODMAP, it incorporates elements of a low FODMAP diet; some patients may, therefore, adapt a low FODMAP diet to one that instead avoids gluten.¹⁰⁴ There have been numerous RCTs of probiotics in IBS but, although some trials show positive results, ability to make recommendations as to which combination, species, or strain is effective is limited due to the wide variety of products studied, and the conflicting results among individual trials.¹⁰⁵

First-line Medical Therapies

Laxatives, antidiarrhoeals, and antispasmodics are all used first-line in IBS. Most RCTs of these drugs are old, and are hampered by suboptimal methodology and heterogeneous patient selection, meaning that efficacy according to predominant stool pattern is uncertain. In addition, efficacy endpoints do not meet current recommendations from the Food and Drug Administration (FDA) or European Medicines Agency (EMA). Although osmotic and stimulant laxatives are efficacious in chronic constipation,¹⁰⁶ there is little evidence for their use in IBS. A placebo-controlled trial of polyethylene glycol in 139 patients with IBS-C demonstrated an increased number of bowel movements, but no improvement in abdominal pain.¹⁰⁷ Similarly, there are only a few small RCTs of antidiarrhoeals, such as loperamide.⁶ Nevertheless, some patients find laxatives or antidiarrhoeals useful. Antispasmodic drugs were more efficacious than placebo in a meta-analysis of 26 trials (RR of remaining symptomatic 0.65; 95% CI 0.56 to 0.76), although side effects were more common (RR 1.60; 95% CI 1.15 to 2.21).⁶ In terms of individual drugs, otilonium, cimetropium, pinaverium, and hyoscine had the most evidence for efficacy;

availability is an issue in some countries. A 4-week RCT of pinaverium, recruiting Chinese patients with IBS-D, and which used FDA-recommended endpoints, demonstrated a significant benefit of the drug over placebo for both abdominal pain and diarrhoea,¹⁰⁸ suggesting antispasmodics may be efficacious in IBS-D. Peppermint oil also appeared superior to placebo in a meta-analysis of seven RCTs (RR of remaining symptomatic 0.54; 95% CI 0.39 to 0.76),⁶ although a subsequent placebo-controlled trial of small intestinal or ileocolonic-release formulations did not demonstrate efficacy for either FDA or EMA-recommended endpoints.¹⁰⁹

Second-line Medical Therapies

Given the accepted role of the gut-brain axis in IBS, the use of antidepressant drugs and CNS targeted medications, or central neuromodulators, as a potential therapy is logical. There is some evidence for efficacy of TCAs; a meta-analysis of 12 RCTs reported a RR of remaining symptomatic of 0.65 (95% CI 0.55 to 0.77) compared with placebo, but trial quality was low and in most RCTs patients were not recruited according to predominant stool pattern.¹¹⁰ Adverse events were more common (RR 1.56; 95% CI 1.23 to 1.98). TCAs have neuromodulatory properties and also slow gastrointestinal transit,¹¹¹ so may be best for patients with predominant pain and/or diarrhoea. Evidence for efficacy of selective serotonin reuptake inhibitors (SSRIs) in the same meta-analysis was less convincing.¹¹⁰ A 12-week placebo-controlled trial of pregabalin in 85 patients failed to demonstrate adequate relief of symptoms, but there were significant improvements in global symptoms, pain, diarrhoea, and bloating.¹¹² All other second-line therapies are licensed and are used based on predominant stool pattern.

5-HT₄ receptor agonists accelerate gastrointestinal transit. Tegaserod was more efficacious than placebo in IBS-C,¹¹³ but was withdrawn due to a small excess number of

cerebrovascular and cardiovascular ischaemic events. It was reintroduced in the USA in 2018 for female patients <65 years without existing cardiovascular disease. Prucalopride, another 5-HT₄ agonist, was superior to placebo in chronic constipation;¹⁰⁶ there are no RCTs in IBS-C. Intestinal secretagogues, such as lubiprostone, linaclotide, plecanatide, and tenapanor act on ion channels in enterocytes, leading to water efflux, thereby accelerating gastrointestinal transit and improving stool consistency. Placebo-controlled trials have demonstrated efficacy of these drugs in IBS-C;¹¹⁴⁻¹¹⁷ there have been no head-to-head trials. A network meta-analysis of 15 RCTs demonstrated similar efficacy for all drugs, but linaclotide was ranked first for improvements in global symptoms, abdominal pain, and stool frequency; tenapanor ranked first for improvement in bloating.¹¹⁸ Diarrhoea was the most common adverse event with all drugs except lubiprostone, which causes nausea in up to 20% of patients.¹¹⁸

Licensed therapies for IBS-D include the 5-HT₃ antagonists alosetron and ramosetron, a peripherally acting mixed opioid receptor agonist/antagonist eluxadoline, and the minimally absorbed antibiotic rifaximin. 5-HT₃ antagonists and eluxadoline slow gastrointestinal transit and reduce visceral hypersensitivity.¹¹⁹ 5-HT₃ antagonists also alter rectal compliance.¹²⁰ Rifaximin has been tested on the basis that alterations in the gastrointestinal microbiota and SIBO may, in part, be responsible for symptoms in IBS; the exact mechanism of action remains uncertain.¹²¹ Although all these drugs have demonstrated efficacy over placebo,^{113,122-124} again there have been no head-to-head trials. A network meta-analysis of 18 RCTs demonstrated that 5-HT₃ receptor antagonists ranked first for improvement in global symptoms, abdominal pain, and stool consistency.¹²⁵ All drugs, except rifaximin, were more likely to cause constipation than placebo. A crossover placebo-controlled trial of ondansetron, another 5-HT₃ antagonist, in 120 patients with IBS-D demonstrated significant improvements in stool consistency and urgency, but not pain;¹²⁶ a large RCT is ongoing.¹²⁷

Figure 5 outlines the spectrum of medications available for pain, constipation, and diarrhoea in IBS, as well as drugs in development. Overall, there is a plethora of choices for diarrhoea or constipation, but still an unmet clinical need for relief of pain.

Psychological Therapies

Similar to central neuromodulators, psychological therapies may exert not only central effects on mood, but also peripheral effects on pain perception, visceral hypersensitivity, and gastrointestinal motility.^{128,129} A meta-analysis of 36 RCTs demonstrated that cognitive behavioural therapy (CBT), gut-directed hypnotherapy, relaxation therapy, multi-component psychological therapy, and dynamic psychotherapy were all more effective than a control intervention.¹¹⁰ Some have evidence for efficacy out to 12 months of follow-up.¹³⁰ These may be intensive, in terms of hours of therapist contact, but subsequent RCTs demonstrate that minimal contact CBT, CBT via the telephone, and group gut-directed hypnotherapy are also effective, even for patients whose symptoms are refractory to medical therapy.¹³¹⁻¹³³ Whether earlier intervention with psychological therapies can change the natural history of IBS, or whether augmentative therapy with a psychological therapy and a central neuromodulator has additive benefit, is unclear.

FUTURE DIRECTIONS AND CONTROVERSIES

Reasons for the difference in prevalence of IBS across different countries, remain uncertain, and prevalence data from certain regions are lacking. Our understanding of the epidemiology is likely to increase as the Rome Foundation global cross-sectional survey database of 73,076 participants is mined further.¹⁵ Despite considerable efforts, a biomarker for IBS remains elusive. A validation study of antibodies to bacterial toxins and host cell adhesion proteins performed only modestly in distinguishing IBS from health.¹³⁴ A case-

control study reported distinct faecal and urinary metabolomic profiles in those with IBS,¹³⁵ which might allow the development of microbe-based treatments. The efficacy of probiotics and faecal microbiota transplantation is inconsistent,^{105,136} although a RCT of faecal microbiota transplantation using a single, healthy, well-characterised donor demonstrated efficacy.¹³⁷ However, more than 50% of patients in this trial continued to have moderate to severe symptoms. With the discovery of actionable biomarkers to identify the mechanisms underlying symptoms the hope is that, in the future, IBS therapy will move away from drugs targeting the predominant symptom, or symptoms, towards one where patients are stratified based on underlying pathophysiology, using these biomarkers, in order to facilitate individualised treatment.¹³⁸

Other pharmacological therapies are in development (Figure 5). Drugs that reduce uptake of sodium ions from the lumen, via transporters expressed in the intestine, result in water retention in the lumen and looser stools. These include mizagliflozin, a sodium-glucose cotransporter-1 inhibitor, and DRAinh-A250, an inhibitor of the solute carrier 26A3. In a phase 2 placebo-controlled trial of mizagliflozin in patients with chronic constipation, response rates were significantly higher with 5mg and 10mg doses, and the medication appeared safe,¹³⁹ albeit after only 1 week of treatment. When administered intraluminally, DRAinh-A250 blocked fluid absorption in mouse colonic loops and reversed loperamide-induced constipation;¹⁴⁰ there are no human studies to date.

Bile acids are physiological laxatives, and are implicated in the pathophysiology of IBS.⁴⁸ Inhibition of the ileal bile acid transporter by elobixibat accelerated colonic transit in patients with constipation,¹⁴¹ and a trial in Japan demonstrated that a 10mg dose was efficacious in patients with constipation, including IBS-C.¹⁴² Although the drug is licensed in Japan, adverse events occurred in 30% of patients, particularly diarrhoea and abdominal pain, and this was only a 2-week trial.

Novel analgesic approaches include further refinements of existing secretagogues. Cyclic GMP (cGMP) production in enterocytes is stimulated by some of these drugs, such as linaclotide. When transported into the extracellular space at the basolateral membrane,¹⁴³ cGMP leads to decreased conduction of submucosal afferent nociceptive neurons, attenuating visceral pain.¹⁴⁴ A preliminary RCT of targeted colonic delivery of linaclotide in patients with IBS-C demonstrated pain relief, without effects on constipation,¹⁴⁵ suggesting that cGMP release from enterocytes reduces the function of peripheral visceral afferents.

When conventional opioids bind to μ -opioid receptors, they induce analgesia through activation of G protein-mediated pathways, but they also activate β -arrestin, which inhibits gastrointestinal motility and depresses central functions, such as cognition and respiration. New biased μ -opioid receptor ligands activate the G protein pathway exclusively, leading to analgesia with reduced gastrointestinal dysfunction.¹⁴⁶ Oliceridine is a biased μ -opioid receptor ligand with comparable analgesic effects to morphine although there are, as yet, no human studies in visceral pain.¹⁴⁷ The cannabinoid type-2 receptor agonist, olotinab, has the potential to alter immune function, as well as sensation, given expression of cannabinoid type-2 receptors in the brain, peripheral nervous system, and gastrointestinal tract. In an open-label trial in patients with quiescent Crohn's disease, it reduced abdominal pain and improved bowel movements.¹⁴⁸ Clinical trials are being conducted in IBS.¹⁴⁹ The histamine-₁ receptor antagonist ebastine appears to attenuate visceral hypersensitivity *in vitro*¹⁵⁰ and, in a RCT of 45 patients, led to significant improvements in both global symptoms and abdominal pain compared with placebo;¹⁵⁰ a larger trial is in progress.¹⁵¹

In summary, the greater understanding of pathophysiological mechanisms in IBS has ushered in the development of novel treatment strategies to manage patients, particularly the abdominal pain component of IBS, for which central neuromodulators or psychological therapies are currently the main approaches. The diverse molecular mechanisms to which

drugs in development are targeted augurs for substantial impact in the management of IBS in the foreseeable future. Nevertheless, a strong doctor-patient relationship with attention to the clinical history, an appreciation of the impact of symptoms on the patient's life, together with an explanation of the condition and its natural history, and shared decision-making, remain key to effective management.

Contributors

ACF, ADS, MC, and MC did the literature search, wrote the manuscript, and drafted the figures. ACF and MC revised the initial manuscript. All authors critically revised subsequent versions of the manuscript and approved the final version of the manuscript.

Declaration of Interests

ACF has no conflicts of interest. ADS has no conflicts of interest. MC has acted as a consultant to Allergan outside the submitted work. MC reports grant from Allergan, grant from Novartis, grant from Takeda, and other from Allergan, Ironwood, Arena, Takeda (consulting with fees going to employer, Mayo Clinic), outside the submitted work.

REFERENCES

1. Buono JL, Carson RT, Flores NM. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. *Health Qual Life Outcomes* 2017; **15**: 35.
2. Frandemark A, Tornblom H, Jakobsson S, Simren M. Work productivity and activity impairment in irritable bowel syndrome (IBS): A multifaceted problem. *Am J Gastroenterol* 2018; **113**: 1540-9.
3. Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. *Lancet Gastroenterol Hepatol* 2016; **1**: 133-46.
4. Sperber AD, Dumitrascu D, Fukudo S, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: A Rome Foundation working team literature review. *Gut* 2017; **66**: 1075-82.
5. Mearin F, Lacy BE, Chang L, et al. Bowel disorders. *Gastroenterology* 2016; **150**: 1393-407.
6. Ford AC, Moayyedi P, Chey WD, et al. American College of Gastroenterology monograph on management of irritable bowel syndrome. *Am J Gastroenterol* 2018; **113** (Suppl 2): 1-18.
7. Flacco ME, Manzoli L, De Giorgio R, et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: A meta-analysis. *Eur Rev Med Pharmacol Sci* 2019; **23**: 2986-3000.

- 571 8. Zhang F, Xiang W, Li CY, Li SC. Economic burden of irritable bowel syndrome in
572 China. *World J Gastroenterol* 2016; **22**: 10450-60.
- 573 9. Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver,
574 and pancreatic diseases in the United States: Update 2018. *Gastroenterology* 2019; **156**: 254-
575 72.e11.
- 576 10. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time.
577 *Scand J Gastroenterol* 1997; **32**: 920-4.
- 578 11. Sperber AD, Gwee KA, Hungin AP, et al. Conducting multinational, cross-cultural
579 research in the functional gastrointestinal disorders: Issues and recommendations. A Rome
580 Foundation working team report. *Aliment Pharmacol Ther* 2014; **40**: 1094-102.
- 581 12. Van den Houde K, Carbone F, Pannemans J, et al. Prevalence and impact of self-
582 reported irritable bowel symptoms in the general population. *United European Gastroenterol*
583 *J* 2019; **7**: 307-15.
- 584 13. Lovell RM, Ford AC. Global prevalence of, and risk factors for, irritable bowel
585 syndrome: A meta-analysis. *Clin Gastroenterol Hepatol* 2012; **10**: 712-21.
- 586 14. Schmulson M, Ortiz O, Santiago-Lomeli M, et al. Frequency of functional bowel
587 disorders among healthy volunteers in Mexico City. *Dig Dis* 2006; **24**: 342-7.

- 588 15. Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden
589 of functional gastrointestinal disorders, results of Rome Foundation global study.
590 *Gastroenterology* 2020; doi:10.1053/j.gastro.2020.04.014.
- 591 16. Petersen MW, Schröder A, Jørgensen T, et al. The unifying diagnostic construct of
592 bodily distress syndrome (BDS) was confirmed in the general population. *J Psychosom Res*
593 2020; **128**: 109868.
- 594 17. Card T, Enck P, Barbara G, et al. Post-infectious IBS: Defining its clinical features
595 and prognosis using an internet-based survey. *United European Gastroenterol J* 2018; **6**:
596 1245-53.
- 597 18. Klem F, Wadhwa A, Prokop LJ, et al. Prevalence, risk factors, and outcomes of
598 irritable bowel syndrome after infectious enteritis: A systematic review and meta-analysis.
599 *Gastroenterology* 2017; **152**: 1042-54.e1.
- 600 19. Donnachie E, Schneider A, Mehring M, Enck P. Incidence of irritable bowel
601 syndrome and chronic fatigue following GI infection: A population-level study using
602 routinely collected claims data. *Gut* 2018; **67**: 1078-86.
- 603 20. Marshall JK, Thabane M, Garg AX, et al. Eight year prognosis of postinfectious
604 irritable bowel syndrome following waterborne bacterial dysentery. *Gut* 2010; **59**: 605-11.
- 605 21. Ringel Y, Sperber AD, Drossman DA. Irritable bowel syndrome. *Annu Rev Med*
606 2001; **52**: 319-38.

- 607 22. Drossman DA. Presidential address: Gastrointestinal illness and the biopsychosocial
608 model. *Psychosom Med* 1998; **60**: 258-67.
- 609 23. Koloski NA, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley NJ. The brain--gut
610 pathway in functional gastrointestinal disorders is bidirectional: A 12-year prospective
611 population-based study. *Gut* 2012; **61**: 1284-90.
- 612 24. Koloski NA, Jones M, Talley NJ. Evidence that independent gut-to-brain and brain-
613 to-gut pathways operate in the irritable bowel syndrome and functional dyspepsia: A 1-year
614 population-based prospective study. *Aliment Pharmacol Ther* 2016; **44**: 592-600.
- 615 25. Tillisch K, Mayer EA, Labus JS. Quantitative meta-analysis identifies brain regions
616 activated during rectal distension in irritable bowel syndrome. *Gastroenterology* 2011; **140**:
617 91-100.
- 618 26. Posserud I, Syrous A, Lindstrom L, Tack J, Abrahamsson H, Simren M. Altered rectal
619 perception in irritable bowel syndrome is associated with symptom severity.
620 *Gastroenterology* 2007; **133**: 1113-23.
- 621 27. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the
622 irritable colon syndrome. *Gut* 1973; **14**: 125-32.
- 623 28. Sullivan MA, Cohen S, Snape WJ, Jr. Colonic myoelectrical activity in irritable-
624 bowel syndrome. Effect of eating and anticholinergics. *N Engl J Med* 1978; **298**: 878-83.

- 625 29. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is
626 correlated with symptoms. *Gastroenterology* 1987; **92**: 1885-93.
- 627 30. Spiller RC, Brown ML, Phillips SF. Emptying of the terminal ileum in intact humans.
628 Influence of meal residue and ileal motility. *Gastroenterology* 1987; **92**: 724-9.
- 629 31. Camilleri M, McKinzie S, Busciglio I, et al. Prospective study of motor, sensory,
630 psychologic, and autonomic functions in patients with irritable bowel syndrome. *Clin*
631 *Gastroenterol Hepatol* 2008; **6**: 772-81.
- 632 32. Simren M, Tornblom H, Palsson OS, Van Oudenhove L, Whitehead WE, Tack J.
633 Cumulative effects of psychologic distress, visceral hypersensitivity, and abnormal transit on
634 patient-reported outcomes in irritable bowel syndrome. *Gastroenterology* 2019; **157**: 391-
635 402.e2.
- 636 33. Bohn L, Storsrud S, Tornblom H, Bengtsson U, Simren M. Self-reported food-related
637 gastrointestinal symptoms in IBS are common and associated with more severe symptoms
638 and reduced quality of life. *Am J Gastroenterol* 2013; **108**: 634-41.
- 639 34. Shepherd SJ, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal
640 symptoms in patients with irritable bowel syndrome: Randomized placebo-controlled
641 evidence. *Clin Gastroenterol Hepatol* 2008; **6**: 765-71.
- 642 35. Major G, Pritchard S, Murray K, et al. Colon hypersensitivity to distension, rather
643 than excessive gas production, produces carbohydrate-related symptoms in individuals with
644 irritable bowel syndrome. *Gastroenterology* 2017; **152**: 124-33.e2.

- 645 36. Thingholm L, Ruhlemann M, Wang J, et al. Sucrase-isomaltase 15Phe IBS risk
646 variant in relation to dietary carbohydrates and faecal microbiota composition. *Gut* 2019; **68**:
647 177-8.
- 648 37. Zheng T, Eswaran S, Photenhauer AL, Merchant JL, Chey WD, D'Amato M.
649 Reduced efficacy of low FODMAPs diet in patients with IBS-D carrying sucrase-isomaltase
650 (SI) hypomorphic variants. *Gut* 2020; **69**: 397-8.
- 651 38. Henstrom M, Diekmann L, Bonfiglio F, et al. Functional variants in the sucrase-
652 isomaltase gene associate with increased risk of irritable bowel syndrome. *Gut* 2018; **67**: 263-
653 70.
- 654 39. Garcia-Etxebarria K, Zheng T, Bonfiglio F, et al. Increased prevalence of rare
655 sucrase-isomaltase pathogenic variants in irritable bowel syndrome patients. *Clin*
656 *Gastroenterol Hepatol* 2018; **16**: 1673-6.
- 657 40. Jalanka-Tuovinen J, Salojärvi J, Salonen A, et al. Faecal microbiota composition and
658 host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel
659 syndrome. *Gut* 2014; **63**: 1737-45.
- 660 41. Sundin J, Rangel I, Fuentes S, et al. Altered faecal and mucosal microbial
661 composition in post-infectious irritable bowel syndrome patients correlates with mucosal
662 lymphocyte phenotypes and psychological distress. *Aliment Pharmacol Ther* 2015; **41**: 342-
663 51.

- 664 42. Pittayanon R, Lau JT, Yuan Y, et al. Gut microbiota in patients with irritable bowel
665 syndrome: A systematic review. *Gastroenterology* 2019; **157**: 97-108.
- 666 43. Krogsgaard LR, Engsbro AL, Bytzer P. Antibiotics: A risk factor for irritable bowel
667 syndrome in a population-based cohort. *Scand J Gastroenterol* 2018; **53**: 1027-30.
- 668 44. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth
669 reduces symptoms of irritable bowel syndrome. *Am J Gastroenterol* 2000; **95**: 3503-6.
- 670 45. Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose
671 hydrogen breath testing demonstrate that breath testing detects oro-caecal transit , not small
672 intestinal bacterial overgrowth in patients with IBS. *Gut* 2011; **60**: 334-40.
- 673 46. Posserud I, Stotzer PO, Bjornsson ES, Abrahamsson H, Simren M. Small intestinal
674 bacterial overgrowth in patients with irritable bowel syndrome. *Gut* 2007; **56**: 802-8.
- 675 47. Slattery SA, Niaz O, Aziz Q, Ford AC, Farmer AD. Systematic review with meta-
676 analysis: The prevalence of bile acid malabsorption in the irritable bowel syndrome with
677 diarrhoea. *Aliment Pharmacol Ther* 2015; **42**: 3-11.
- 678 48. Shin A, Camilleri M, Vijayvargiya P, et al. Bowel functions, fecal unconjugated
679 primary and secondary bile acids, and colonic transit in patients with irritable bowel
680 syndrome. *Clin Gastroenterol Hepatol* 2013; **11**: 1270-5.

- 681 49. Camilleri M, Busciglio I, Acosta A, et al. Effect of increased bile acid synthesis or
682 fecal excretion in irritable bowel syndrome-diarrhea. *Am J Gastroenterol* 2014; **109**: 1621-
683 30.
- 684 50. Zhao L, Yang W, Chen Y, et al. A Clostridia-rich microbiota enhances bile acid
685 excretion in diarrhea-predominant irritable bowel syndrome. *J Clin Invest* 2020; **130**: 438-50.
- 686 51. Marshall JK, Thabane M, Garg AX, Clark W, Meddings J, Collins SM. Intestinal
687 permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute
688 gastroenteritis in Walkerton, Ontario. *Aliment Pharmacol Ther* 2004; **20**: 1317-22.
- 689 52. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological
690 features of postinfective irritable bowel syndrome. *Am J Gastroenterol* 2003; **98**: 1578-83.
- 691 53. Balemans D, Mondelaers SU, Cibert-Goton V, et al. Evidence for long-term
692 sensitization of the bowel in patients with post-infectious-IBS. *Sci Rep* 2017; **7**: 13606.
- 693 54. Gecse K, Roka R, Sera T, et al. Leaky gut in patients with diarrhea-predominant
694 irritable bowel syndrome and inactive ulcerative colitis. *Digestion* 2012; **85**: 40-6.
- 695 55. Bashashati M, Moossavi S, Cremon C, et al. Colonic immune cells in irritable bowel
696 syndrome: A systematic review and meta-analysis. *Neurogastroenterol Motil* 2018; **30**: doi:
697 10.1111/nmo.13192.

- 698 56. Bonfiglio F, Zheng T, Garcia-Etxebarria K, et al. Female-specific association between
699 variants on chromosome 9 and self-reported diagnosis of irritable bowel syndrome.
700 *Gastroenterology* 2018; **155**: 168-79.
- 701 57. Beyder A, Mazzone A, Strege PR, et al. Loss-of-function of the voltage-gated sodium
702 channel NaV1.5 (channelopathies) in patients with irritable bowel syndrome.
703 *Gastroenterology* 2014; **146**: 1659-68.
- 704 58. Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA. Irritable bowel
705 syndrome in twins: Heredity and social learning both contribute to etiology.
706 *Gastroenterology* 2001; **121**: 799-804.
- 707 59. Jafri W, Yakoob J, Jafri N, Islam M, Masroor Ali Q. Irritable bowel syndrome and
708 health seeking behaviour in different communities of Pakistan. *J Pak Med Assoc* 2007; **57**:
709 285-7.
- 710 60. Patel P, Bercik P, Morgan DG, et al. Irritable bowel syndrome is significantly
711 associated with somatisation in 840 patients, which may drive bloating. *Aliment Pharmacol*
712 *Ther* 2015; **14**(10): 13074.
- 713 61. Zamani M, Alizadeh-Tabari S, Zamani V. Systematic review with meta-analysis: The
714 prevalence of anxiety and depression in patients with irritable bowel syndrome. *Aliment*
715 *Pharmacol Ther* 2019; **50**: 132-43.
- 716 62. Aziz I, Palsson OS, Tornblom H, Sperber AD, Whitehead WE, Simren M. The
717 prevalence and impact of overlapping Rome IV-diagnosed functional gastrointestinal

- 718 disorders on somatization, quality of life, and healthcare utilization: A cross-sectional general
719 population study in three countries. *Am J Gastroenterol* 2018; **113**: 86-96.
- 720 63. Gwee KA, Wee S, Wong ML, Png DJ. The prevalence, symptom characteristics, and
721 impact of irritable bowel syndrome in an Asian urban community. *Am J Gastroenterol* 2004;
722 **99**: 924-31.
- 723 64. Palsson OS, Baggish JS, Turner MJ, Whitehead WE. IBS patients show frequent
724 fluctuations between loose/watery and hard/lumpy stools: Implications for treatment. *Am J*
725 *Gastroenterol* 2012; **107**: 286-95.
- 726 65. Houghton LA, Lea R, Agrawal A, Reilly B, Whorwell PJ. Relationship of abdominal
727 bloating to distention in irritable bowel syndrome and effect of bowel habit.
728 *Gastroenterology* 2006; **131**: 1003-10.
- 729 66. Spiegel BM, Gralnek IM, Bolus R, et al. Is a negative colonoscopy associated with
730 reassurance or improved health-related quality of life in irritable bowel syndrome?
731 *Gastrointest Endosc* 2005; **62**: 892-9.
- 732 67. Adeniji OA, Barnett CB, Di Palma JA. Durability of the diagnosis of irritable bowel
733 syndrome based on clinical criteria. *Dig Dis Sci* 2004; **49**: 572-4.
- 734 68. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P.
735 Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary
736 care. *Gastroenterology* 2013; **145**: 1262-70.

69. Sood R, Camilleri M, Gracie DJ, et al. Enhancing diagnostic performance of symptom-based criteria for irritable bowel syndrome by additional history and limited diagnostic evaluation. *Am J Gastroenterol* 2016; **111**: 1446-554.
70. Irvine AJ, Chey WD, Ford AC. Screening for celiac disease in irritable bowel syndrome: An updated systematic review and meta-analysis. *Am J Gastroenterol* 2017; **112**: 65-76.
71. Suspected cancer: recognition and referral.
<https://www.nice.org.uk/guidance/ng12/chapter/Introduction#lower-gastrointestinal-tract-cancers> 2015. Accessed 14th December 2019
72. Brandler J, Camilleri M. Pretest and post-test probabilities of diagnoses of rectal evacuation disorders based on symptoms, rectal exam, and basic tests: A systematic review. *Clin Gastroenterol Hepatol* 2019; doi: **10.1016/j.cgh.2019.11.049**.
73. Rao SS, Valestin J, Brown CK, Zimmerman B, Schulze K. Long-term efficacy of biofeedback therapy for dyssynergic defecation: Randomized controlled trial. *Am J Gastroenterol* 2010; **105**: 890-6.
74. The new faecal calprotectin care pathway.
<https://www.nice.org.uk/sharedlearning/the-new-faecal-calprotectin-care-pathway> 2018.
Accessed 14th December 2019
75. Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin

757 to exclude inflammatory bowel disease in adults with IBS. *Am J Gastroenterol* 2015; **110**:
758 444-54.

759 76. Chey WD, Nojkov B, Rubenstein JH, Dobhan R, Greenson JK, Cash BD. The yield of
760 colonoscopy in patients with non-constipated irritable bowel syndrome: Results from a
761 prospective, controlled US trial. *Am J Gastroenterol* 2010; **105**: 859-65.

762 77. Macaigne G, Lahmek P, Locher C, et al. Microscopic colitis or functional bowel
763 disease with diarrhea: a French prospective multicenter study. *Am J Gastroenterol* 2014; **109**:
764 1461-70.

765 78. Kane JS, Rotimi O, Everett SM, Samji S, Michelotti F, Ford AC. Development and
766 validation of a scoring system to identify patients with microscopic colitis. *Clin*
767 *Gastroenterol Hepatol* 2015; **13**: 1125-31.

768 79. Vijayvargiya P, Camilleri M. Current practice in the diagnosis of bile acid diarrhea.
769 *Gastroenterology* 2019; **156**: 1233-8.

770 80. Orekoya O, McLaughlin J, Leitaio E, Johns W, Lal S, Paine P. Quantifying bile acid
771 malabsorption helps predict response and tailor sequestrant therapy. *Clin Med (Lond)* 2015;
772 **15**: 252-7.

773 81. Arasaradnam RP, Brown S, Forbes A, et al. Guidelines for the investigation of
774 chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition. *Gut* 2018; **67**:
775 1380-99.

- 776 82. Ford AC, Forman D, Bailey AG, Axon ATR, Moayyedi P. Irritable bowel syndrome:
777 A 10-year natural history of symptoms, and factors that influence consultation behavior. *Am J*
778 *Gastroenterol* 2008; **103**: 1229-39.
- 779 83. Halder SLS, Locke III GR, Schleck CD, Zinsmeister AR, Melton III LJ, Talley NJ.
780 Natural history of functional gastrointestinal disorders: A 12-year longitudinal population-
781 based study. *Gastroenterology* 2007; **133**: 799-807.
- 782 84. Olafsdottir LB, Gudjonsson H, Jonsdottir HH, Bjornsson E, Thjodleifsson B. Natural
783 history of functional gastrointestinal disorders: Comparison of two longitudinal population-
784 based studies. *Dig Liver Dis* 2012; **44**: 211-7.
- 785 85. Chang JY, Locke III GR, McNally MA, et al. Impact of functional gastrointestinal
786 disorders on survival in the community. *Am J Gastroenterol* 2010; **105**: 822-32.
- 787 86. Pace F, Molteni P, Bollani S, et al. Inflammatory bowel disease versus irritable bowel
788 syndrome: A hospital-based, case-control study of disease impact on quality of life. *Scand J*
789 *Gastroenterol* 2003; **38**: 1031-8.
- 790 87. Black CJ, Yiannakou Y, Houghton LA, Ford AC. Epidemiological, clinical, and
791 psychological characteristics of individuals with self-reported irritable bowel syndrome based
792 on the Rome IV vs Rome III criteria. *Clin Gastroenterol Hepatol* 2020; **18**: 392-8.
- 793 88. Ballou S, McMahon C, Lee HN, et al. Effects of irritable bowel syndrome on daily
794 activities vary among subtypes based on results from the IBS in America survey. *Clin*
795 *Gastroenterol Hepatol* 2019; **17**: 2471-8.e3.

- 796 89. Ringstrom G, Abrahamsson H, Strid H, Simren M. Why do subjects with irritable
797 bowel syndrome seek health care for their symptoms? *Scand J Gastroenterol* 2007; **42**: 1194-
798 203.
- 799 90. Lacy BE, Everhart KK, Weiser KT, et al. IBS patients' willingness to take risks with
800 medications. *Am J Gastroenterol* 2012; **107**: 804-9.
- 801 91. Hulme K, Chilcot J, Smith MA. Doctor-patient relationship and quality of life in
802 irritable bowel syndrome: An exploratory study of the potential mediating role of illness
803 perceptions and acceptance. *Psychol Health Med* 2018; **23**: 674-84.
- 804 92. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: Long-term
805 prognosis and the physician-patient interaction. *Ann Intern Med* 1995; **122**: 107-12.
- 806 93. Drossman DA. 2012 David Sun lecture: Helping your patient by helping yourself--
807 how to improve the patient-physician relationship by optimizing communication skills. *Am J*
808 *Gastroenterol* 2013; **108**: 521-8.
- 809 94. Ringström G, Störsrud S, Posserud I, Lundqvist S, Westman B, Simrén M. Structured
810 patient education is superior to written information in the management of patients with
811 irritable bowel syndrome: A randomized controlled study. *Eur J Gastroenterol Hepatol* 2010;
812 **22**: 420-8.
- 813 95. Johannesson E, Simren M, Strid H, Bajor A, Sadik R. Physical activity improves
814 symptoms in irritable bowel syndrome: A randomized controlled trial. *Am J Gastroenterol*
815 2011; **106**: 915-22.

- 816 96. Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal.
817 *Lancet* 1994; **344**: 39-40.
- 818 97. Moayyedi P, Quigley EM, Lacy BE, et al. The effect of fiber supplementation on
819 irritable bowel syndrome: A systematic review and meta-analysis. *Am J Gastroenterol* 2014;
820 **109**: 1367-74.
- 821 98. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs
822 reduces symptoms of irritable bowel syndrome. *Gastroenterology* 2014; **146**: 67-75.
- 823 99. Staudacher HM, Lomer MC, Anderson JL, et al. Fermentable carbohydrate restriction
824 reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel
825 syndrome. *J Nutr* 2012; **142**: 1510-8.
- 826 100. Eswaran SL, Chey WD, Han-Markey T, Ball S, Jackson K. A randomized controlled
827 trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-
828 D. *Am J Gastroenterol* 2016; **111**: 1824-32.
- 829 101. Bohn L, Storsrud S, Liljebo T, et al. Diet low in FODMAPs reduces symptoms of
830 irritable bowel syndrome as well as traditional dietary advice: A randomized controlled trial.
831 *Gastroenterology* 2015; **149**: 1399-407.e2.
- 832 102. Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG. Diets
833 that differ in their FODMAP content alter the colonic luminal microenvironment. *Gut* 2015;
834 **64**: 93-100.

- 835 103. Dionne J, Ford AC, Yuan Y, et al. A systematic review and meta-analysis evaluating
836 the efficacy of a gluten-free diet and a low FODMAPs diet in treating symptoms of irritable
837 bowel syndrome. *Am J Gastroenterol* 2018; **113**: 1290-300.
- 838 104. O'Keeffe M, Jansen C, Martin L, et al. Long-term impact of the low-FODMAP diet
839 on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization
840 in irritable bowel syndrome. *Neurogastroenterol Motil* 2018; **30**: doi: 10.1111/nmo.13154.
- 841 105. Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with
842 meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable
843 bowel syndrome. *Aliment Pharmacol Ther* 2018; **48**: 1044-60.
- 844 106. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic
845 idiopathic constipation: Systematic review and meta-analysis. *Gut* 2011; **60**: 209-18.
- 846 107. Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial:
847 Macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated
848 with irritable bowel syndrome. *Am J Gastroenterol* 2013; **108**: 1508-15.
- 849 108. Zheng L, Lai Y, Lu W, et al. Pinaverium reduces symptoms of irritable bowel
850 syndrome in a multi-center, randomized controlled trial. *Clin Gastroenterol Hepatol* 2015;
851 **13**: 1285-92.
- 852 109. Weerts ZZRM, Masclee AAM, Wittteman BJM, et al. Efficacy and safety of
853 peppermint oil in a randomized double-blind trial of patients with irritable bowel syndrome.
854 *Gastroenterology* 2020; **158**: 123-36.

- 855 110. Ford AC, Lacy BE, Harris LA, Quigley EM, Moayyedi P. Effect of antidepressants
856 and psychological therapies in irritable bowel syndrome: An updated systematic review and
857 meta-analysis. *Am J Gastroenterol* 2019; **114**: 21-39.
- 858 111. Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small
859 intestinal motility in health and diarrhea-predominant irritable bowel syndrome. *Dig Dis Sci*
860 1995; **40**: 86-95.
- 861 112. Saito YA, Almazar AE, Tilkes KE, et al. Randomised clinical trial: Pregabalin vs
862 placebo for irritable bowel syndrome. *Aliment Pharmacol Ther* 2019; **49**: 389-97.
- 863 113. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy
864 of 5-HT₃ antagonists and 5-HT₄ agonists in irritable bowel syndrome: Systematic review
865 and meta-analysis. *Am J Gastroenterol* 2009; **104**: 1831-43.
- 866 114. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: Lubiprostone in patients
867 with constipation-associated irritable bowel syndrome - results of two randomized, placebo-
868 controlled studies. *Aliment Pharmacol Ther* 2009; **29**: 329-41.
- 869 115. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with
870 constipation: A 26-week, randomized, double-blind, placebo-controlled trial to evaluate
871 efficacy and safety. *Am J Gastroenterol* 2012; **107**: 1702-12.
- 872 116. Chey WD, Lembo AJ, Rosenbaum DP. Tenapanor treatment of patients with
873 constipation-predominant irritable bowel syndrome: A phase 2, randomized, placebo-
874 controlled efficacy and safety trial. *Am J Gastroenterol* 2017; **112**: 763-74.

- 875 117. Brenner DM, Fogel R, Dorn SD, et al. Efficacy, safety, and tolerability of plecanatide
876 in patients with irritable bowel syndrome with constipation: Results of two phase 3
877 randomized clinical trials *Am J Gastroenterol* 2018; **113**: 735-45.
- 878 118. Black CJ, Burr NE, Quigley EMM, Moayyedi P, Houghton LA, Ford AC. Efficacy of
879 secretagogues in patients with irritable bowel syndrome with constipation: Systematic review
880 and network meta-analysis. *Gastroenterology* 2018; **155**: 1753-63.
- 881 119. Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT₃ receptor antagonist,
882 delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
883 *Aliment Pharmacol Ther* 2000; **14**: 775-82.
- 884 120. Thumshirn M, Coulie B, Camilleri M, Zinsmeister AR, Burton DD, Van Dyke C.
885 Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with
886 irritable bowel syndrome. *Aliment Pharmacol Ther* 2000; **14**: 869-78.
- 887 121. Acosta A, Camilleri M, Shin A, et al. Effects of rifaximin on transit, permeability,
888 fecal microbiome, and organic acid excretion in irritable bowel syndrome. *Clin Transl*
889 *Gastroenterol* 2016; **7**: e173.
- 890 122. Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and
891 effective in patients with diarrhea-predominant irritable bowel syndrome. *Gastroenterology*
892 2016; **151**: 1113-21.
- 893 123. Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome
894 with diarrhea. *N Engl J Med* 2016; **374**: 242-53.

895 124. Fukudo S, Kinoshita Y, Okumura T, et al. Ramosetron reduces symptoms of irritable
896 bowel syndrome with diarrhea and improves quality of life in women. *Gastroenterology*
897 2016; **150**: 358-66.

898 125. Black CJ, Burr NE, Camilleri M, et al. Efficacy of pharmacological therapies in
899 patients with IBS with diarrhoea or mixed stool pattern: Systematic review and network
900 meta-analysis. *Gut* 2020; **69**: 74-82.

901 126. Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the
902 treatment of irritable bowel syndrome with diarrhoea. *Gut* 2014; **63**: 1617-25.

903 127. Gunn D, Fried R, Lalani R, et al. Treatment of irritable bowel syndrome with
904 diarrhoea using titrated ondansetron (TRITON): Study protocol for a randomised controlled
905 trial. *Trials* 2019; **20**: 517.

906 128. Lowen MB, Mayer EA, Sjoberg M, et al. Effect of hypnotherapy and educational
907 intervention on brain response to visceral stimulus in the irritable bowel syndrome. *Aliment*
908 *Pharmacol Ther* 2013; **37**: 1184-97.

909 129. Simren M, Ringstrom G, Bjornsson ES, Abrahamsson H. Treatment with
910 hypnotherapy reduces the sensory and motor component of the gastrocolonic response in
911 irritable bowel syndrome. *Psychosom Med* 2004; **66**: 233-8.

912 130. Black CJ, Thakur ER, Houghton LA, Quigley EMM, Moayyedi P, Ford AC. Efficacy
913 of psychological therapies for irritable bowel syndrome: Systematic review and network
914 meta-analysis. *Gut* 2020; doi: **10.1136/gutjnl-2020-321191**.

- 915 131. Lackner JM, Jaccard J, Keefer L, et al. Improvement in gastrointestinal symptoms
916 after cognitive behavior therapy for refractory irritable bowel syndrome. *Gastroenterology*
917 2018; **155**: 47-57.
- 918 132. Everitt HA, Landau S, O'Reilly G, et al. Assessing telephone-delivered cognitive-
919 behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable
920 bowel syndrome (ACTIB): A multicentre randomised trial. *Gut* 2019; **68**: 1613-23.
- 921 133. Flik CE, Laan W, Zuithoff NPA, et al. Efficacy of individual and group hypnotherapy
922 in irritable bowel syndrome (IMAGINE): A multicentre randomised controlled trial. *Lancet*
923 *Gastroenterol Hepatol* 2019; **4**: 20-31.
- 924 134. Pimentel M, Morales W, Rezaie A, et al. Development and validation of a biomarker
925 for diarrhea-predominant irritable bowel syndrome in human subjects. *PLoS One* 2015; **10**:
926 e0126438.
- 927 135. Jeffery IB, Das A, O'Herlihy E, et al. Differences in fecal microbiomes and
928 metabolomes of people with vs without irritable bowel syndrome and bile acid
929 malabsorption. *Gastroenterology* 2020; **158**: 1016-28.
- 930 136. Ianiro G, Eusebi LH, Black CJ, Gasbarrini A, Cammarota G, Ford AC. Systematic
931 review with meta-analysis: Efficacy of faecal microbiota transplantation for the treatment of
932 irritable bowel syndrome. *Aliment Pharmacol Ther* 2019; **50**: 240-8.

- 933 137. El-Salhy M, Hatlebakk JG, Gilja OH, Bråthen Kristoffersen A, Hausken T. Efficacy
934 of faecal microbiota transplantation for patients with irritable bowel syndrome in a
935 randomised, double-blind, placebo-controlled study. *Gut* 2020; **69**: 859-67.
- 936 138. Camilleri M, Shin A, Busciglio I, et al. Validating biomarkers of treatable
937 mechanisms in irritable bowel syndrome. *Neurogastroenterol Motil* 2014; **26**: 1677-85.
- 938 139. Fukudo S, Endo Y, Hongo M, et al. Safety and efficacy of the sodium-glucose
939 cotransporter 1 inhibitor mizagliflozin for functional constipation: A randomised, placebo-
940 controlled, double-blind phase 2 trial. *Lancet Gastroenterol Hepatol* 2018; **3**: 603-13.
- 941 140. Haggie PM, Cil O, Lee S, et al. SLC26A3 inhibitor identified in small molecule
942 screen blocks colonic fluid absorption and reduces constipation. *JCI insight* 2018; **3**.
- 943 141. Wong BS, Camilleri M, McKinzie S, Burton D, Graffner H, Zinsmeister AR. Effects
944 of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females
945 with functional constipation. *Am J Gastroenterol* 2011; **106**: 2154-64.
- 946 142. Nakajima A, Seki M, Taniguchi S, et al. Safety and efficacy of elobixibat for chronic
947 constipation: Results from a randomised, double-blind, placebo-controlled, phase 3 trial and
948 an open-label, single-arm, phase 3 trial. *Lancet Gastroenterol Hepatol* 2018; **3**: 537-47.
- 949 143. Tchernychev B, Ge P, Kessler MM, et al. MRP4 modulation of the guanylate cyclase-
950 C/cGMP pathway: Effects on linaclotide-induced electrolyte secretion and cGMP efflux. *J*
951 *Pharmacol Exp Ther* 2015; **355**: 48-56.

- 952 144. Castro J, Harrington AM, Hughes PA, et al. Linaclotide inhibits colonic nociceptors
953 and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-
954 monophosphate. *Gastroenterology* 2013; **145**: 1334-46.e1-11.
- 955 145. Chey WD, Chamberlin P, Bochenek W, et al. Targeted delivery of linaclotide to
956 specific areas of the intestine affects clinical efficacy in patients with irritable bowel
957 syndrome with constipation (IBS-C). *Gastroenterology* 2017; **152** (suppl 1): S1314-S5.
- 958 146. DeWire SM, Yamashita DS, Rominger DH, et al. A G protein-biased ligand at the
959 mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory
960 dysfunction compared with morphine. *J Pharmacol Exp Ther* 2013; **344**: 708-17.
- 961 147. Viscusi ER, Skobieranda F, Soergel DG, Cook E, Burt DA, Singla N. APOLLO-1: A
962 randomized placebo and active-controlled phase III study investigating oliceridine (TRV130),
963 a G protein-biased ligand at the micro-opioid receptor, for management of moderate-to-
964 severe acute pain following bunionectomy. *J Pain Res* 2019; **12**: 927-43.
- 965 148. Yacyshyn B, Ginsberg DC, Gilder K, et al. Safety and efficacy of olorinab, a
966 peripherally restricted, highly selective, cannabinoid receptor 2 agonist in a phase 2A study in
967 chronic abdominal pain associated with Crohn's Disease. *Gastroenterology* 2019; **156** (suppl
968 1): S-665.
- 969 149. Olorinab in IBS-C and IBS-D (CAPTIVATE).
970 <https://clinicaltrials.gov/ct2/show/NCT04043455> Accessed 14th December 2019

971 150. Wouters MM, Balemans D, Van Wanrooy S, et al. Histamine receptor H1-mediated
972 sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with
973 irritable bowel syndrome. *Gastroenterology* 2016; **150**: 875-87.e9.

974 151. Peripheral histamine 1 receptor blockade in IBS: Multicenter trial.

975 <https://clinicaltrials.gov/ct2/show/NCT01908465> Accessed 14th December 2019

976

FIGURE LEGENDS.

Figure 1. Global Prevalence of Irritable Bowel Syndrome According to the Rome III Criteria*.

***Note, the prevalence data reported here are taken from studies using the Rome III criteria for IBS, summarised in references 4, 13, and 15.**

Figure 2. Factors Affecting Symptom Severity in Irritable Bowel Syndrome.

Figure 3. Pathophysiological Mechanisms Involved in Irritable Bowel Syndrome.

***Genome-wide association studies have demonstrated associations with variants of chromosome 9 (reference 56), and mutations in the sucrase-isomaltase gene (references 37 and 38), and studies have shown approximately 2% of IBS patients carry mutations in *SCN5A* (reference 57), which alters the function of the voltage-gated mechanosensitive Na⁺ channel Na_v1.5.**

†See references 17 to 20.

±Gastrointestinal symptoms include abdominal pain, abnormal stool form and/or frequency, and bloating (reference 5); non-gastrointestinal symptoms include back pain, gynaecological and bladder symptoms, headache, and fatigue (reference 60).

Figure 4. Suggested Diagnostic Algorithm for Patients with Suspected Irritable Bowel Syndrome.

***Abdominal pain, related to defaecation, associated with change in stool form or stool frequency (reference 5).**

†Full blood count and C-reactive protein/erythrocyte sedimentation rate

±See Table 2.

§Including family history of inflammatory bowel disease, coeliac disease, or colorectal cancer, or features suggestive of microscopic colitis (female, age ≥50 years; co-existent autoimmune disease; proton pump inhibitor or non-steroidal anti-inflammatory drug

use; duration of diarrhoea < 12 months; weight loss; or nocturnal diarrhoea (references 77 and 78)).

‡Consider measuring SeHCAT retention, serum 7 α -hydroxy-4-cholesten-3-one, serum fibroblast growth factor-19, or 48-hour faecal bile acid excretion, where available, or a trial of a bile acid sequestrant, to exclude bile acid diarrhoea.

**If the initial faecal calprotectin level is within the abnormal range the suspicion for inflammatory bowel disease is high, proceed to colonoscopy (reference 74); if the initial faecal calprotectin level is indeterminate according to local laboratory values, repeat the test off non-steroidal anti-inflammatory drugs and refer for colonoscopy if the repeat test remains indeterminate or is within the abnormal range.

††If features suggestive of a defaecatory disorder, including obstructive symptoms (such as a feeling of incomplete evacuation or the need to digitate during defaecation) or paradoxical anal contraction on straining during digital rectal examination, are present consider anorectal manometry with balloon expulsion testing.

Figure 5. Current and Emerging Treatment Options for Irritable Bowel Syndrome.

1018 **Table 1. The Rome IV Criteria for Irritable Bowel Syndrome*.**

Rome IV IBS Diagnostic Criteria			
1. Recurrent abdominal pain, on average, at least 1 day per week in the last 3 months and associated with two or more of the following: a. Related to defaecation; b. Associated with a change in frequency of stool; c. Associated with a change in stool form.			
AND			
2. Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis			
IBS-C	IBS-D	IBS-M	IBS-U
≥25% of bowel movements of Bristol stool form types 1 or 2, and <25% of Bristol stool form types 6 or 7.	≥25% of bowel movements of Bristol stool form types 6 or 7, and <25% of Bristol stool form types 1 or 2.	≥25% of bowel movements of Bristol stool form types 1 or 2, and ≥25% of bowel movements of Bristol stool form types 6 or 7.	Patients who meet criteria for IBS, but who do not fall into one of the other three subgroups according to Bristol stool form type.

1019 ***Adapted from reference 5.**

1020

1021 **Table 2. Lower Gastrointestinal Alarm Symptoms and Signs (Based on the UK's NICE**
1022 **Guidance*).**

Definite Referral Criteria	
•	Aged ≥ 40 years with unexplained weight loss and abdominal pain.
	• Aged ≥ 50 years with unexplained rectal bleeding.
	• Aged ≥ 60 years with change in bowel habit, a positive faecal occult blood test, or iron deficiency anaemia.

1023 ***Adapted from reference 71.** Regardless of age, adults with unexplained rectal bleeding or
1024 iron-deficiency anaemia (especially if accompanied by abdominal pain, change in bowel
1025 habit, or weight loss), or an abdominal or rectal mass, need investigation to exclude other
1026 gastrointestinal disorders, including cancer.

1027

Table 3. Summary of Evidence for Efficacy of Treatment Approaches for Irritable Bowel Syndrome*.

Therapy	Specific Intervention†	IBS Subgroup Studied	Efficacy	Quality of Data	Adverse Events	Limitations of Data
Diet, lifestyle, and probiotics	Soluble fibre (e.g. ispaghula 20 - 30g/day)	No specific IBS subgroup recruited	Effective	Moderate	Total adverse events no more common with soluble fibre in three RCTs	Only one RCT at low risk of bias; only a small number of patients in existing RCTs
	Low FODMAP diet	No specific IBS subgroup recruited	May be effective	Very low	Total adverse events rarely reported	All RCTs at high risk of bias; heterogeneity between study designs; imprecision in estimate of effect; impact of FODMAP reintroduction not studied within the design
	Exercise	No specific IBS subgroup recruited	May be effective	Very low	Total adverse events not reported	Only two RCTs, which were at high risk of bias; inconsistent effects on symptoms
	Probiotics	No specific IBS subgroup recruited	May be effective	Very low	Total adverse events no more common with probiotics in a meta-analysis of 36 RCTs	Heterogeneity between studies; possible publication bias; only a small number of RCTs assessing each individual probiotic, meaning that it is difficult to know which species or strain is effective
First-line therapies	Peppermint oil (200mg three times daily)	No specific IBS subgroup recruited	Effective	Low	Total adverse events no more common with peppermint oil in a meta-analysis of six RCTs	Only two RCTs at low risk of bias; heterogeneity between studies; trials used very specific formulations so data cannot be extrapolated to other available products; heartburn may be an issue
	Laxatives (e.g. polyethylene glycol 13.8g once daily and titrated)	Patients with IBS-C	Unclear efficacy	Low	Rates of abdominal pain numerically higher with polyethylene glycol in one RCT	Only two RCTs; both RCTs unclear risk of bias; effect on abdominal pain unclear
	Antidiarrhoeals (e.g. loperamide 4mg as required)	Patients with IBS-D and IBS-M	Unclear efficacy	Very low	Total adverse events no more common with antidiarrhoeals in two RCTs	Only two RCTs; both RCTs unclear risk of bias; not all patients met criteria for IBS; no significant effect on IBS symptoms when data pooled; constipation may be an issue

	Antispasmodics (e.g. cimetropium 50mg three times daily, hyoscine 10-20 mg three times daily, otilonium 20-40mg three times daily, or pinaverium 50mg three times daily)	No specific IBS subgroup selected, other than one RCT in patients with IBS-D	May be effective	Very low	Total adverse events significantly more common with antispasmodics in a meta-analysis of 26 RCTs, particularly dry mouth, dizziness, and blurred vision	Only two RCTs at low risk of bias; heterogeneity between studies; possible publication bias; only a small number of RCTs assessing each individual antispasmodic
Second-line therapies	5-HT ₄ agonists (e.g. tegaserod 6mg twice daily)	IBS-C	Effective	High	Diarrhoea significantly more common with tegaserod in a meta-analysis of six RCTs	Concerns regarding small excess of cardiovascular and cerebrovascular events led to withdrawal of tegaserod, reintroduced in 2018 but only for specific patients; no RCTs of prucalopride
	Linaclotide (290mcg once daily)	IBS-C	Effective	High	Diarrhoea significantly more common with linaclotide in a meta-analysis of three RCTs	None
	5-HT ₃ antagonists (e.g. alosetron 0.5-1mg twice daily, ramosetron 2.5-5mcg once daily, or ondansetron 4mg once daily and titrated)	IBS-D and IBS-M	Effective	High	Constipation significantly more common with alosetron in a meta-analysis of three RCTs	All RCTs of ramosetron conducted in Japan; serious adverse events with alosetron included ischaemic colitis and severe constipation leading to restricted use; ramosetron is safer, although constipation is still more common with active therapy
	TCAs (e.g. amitriptyline 10-30mg at night or desipramine 50mg at night)	No specific IBS subgroup selected, other than one RCT in patients with IBS-D	Effective	Moderate	Total adverse events significantly more common with TCAs in a meta-analysis of six RCTs, particularly dry mouth and drowsiness	Only three RCTs at low risk of bias; possible publication bias; some atypical trials included
	Lubiprostone (8mcg twice daily)	IBS-C	Effective	Moderate	Nausea significantly more common with lubiprostone in a meta-analysis of three RCTs	Only a modest benefit over placebo in published RCTs
	Plecanatide (3-6mg once daily)	IBS-C	Effective	Moderate	Diarrhoea significantly more common with plecanatide in a meta-analysis of two RCTs	Only a modest benefit over placebo in published RCTs

	Tenapanor (50mg twice daily)	IBS-C	Effective	Moderate	Rates of diarrhoea numerically higher with tenapanor	Awaiting publication of all phase 3 trial data
	Eluxadoline (100mg twice daily)	IBS-D	Effective	Moderate	Rates of constipation, nausea, and vomiting numerically higher with eluxadoline in a pooled analysis of two RCTs	Heterogeneity between studies; only a modest benefit over placebo in published RCTs; no benefit over placebo in terms of abdominal pain; serious adverse events include acute pancreatitis and sphincter of Oddi spasm
	Rifaximin (550mg three times daily)	IBS-D and IBS-M	Effective	Moderate	Total adverse events no more common with rifaximin in a pooled analysis of three RCTs	Only a modest benefit over placebo in published RCTs
	SSRIs (e.g. fluoxetine 20mg once daily)	No specific IBS subgroup selected, other than one RCT in patients with IBS-C	May be effective	Low	Total adverse events no more common with SSRIs	Only one RCT at low risk of bias; heterogeneity between studies
	Pregabalin (225mg twice daily)	No specific IBS subgroup recruited	May be effective	Low	Total adverse events numerically higher with pregabalin, particularly blurred vision, dizziness, and altered sensation	Only one single-centre RCT although global symptoms, abdominal pain, diarrhoea, and bloating improved significantly
Psychological therapies	CBT or gut-directed hypnotherapy	No specific IBS subgroup recruited	Effective	Very low	Adverse events not reported in individual RCTs, precluding their assessment in a meta-analysis of 36 RCTs	All RCTs at high risk of bias due to the nature of the interventions studied; heterogeneity between studies; possible publication bias; only a small number of RCTs assessing each intervention; time consuming due to need for therapist contact; limited availability in some countries

***Data adapted from reference 6.**

†Most drugs should be trialled for 3 months, with their efficacy then reviewed, with the exception of rifaximin, which is a 2-week treatment course. A low FODMAP diet should not be maintained long-term; the restriction phase in RCTs to date has been a maximum of 3 to 4 weeks.